UBS Group
TRVI icon

UBS Group’s Trevi Therapeutics TRVI Stock Holding History

UBS Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Sell
270,498
-175,694
-39% -$2.56M ﹤0.01% 4152
2026
Q1 		$5.32M Buy
446,192
+171,564
+62% +$1.92M ﹤0.01% 4025
2025
Q4 		$3.44M Sell
274,628
-23,984
-8% -$277K ﹤0.01% 4407
2025
Q3 		$2.73M Sell
298,612
-55,613
-16% -$417K ﹤0.01% 4665
2025
Q2 		$1.94M Buy
354,225
+261,192
+281% +$1.63M ﹤0.01% 4856
2025
Q1 		$585K Buy
93,033
+47,518
+104% +$227K ﹤0.01% 5728
2024
Q4 		$188K Buy
45,515
+17,653
+63% +$56.5K ﹤0.01% 6487
2024
Q3 		$93.1K Buy
27,862
+9,853
+55% +$29.3K ﹤0.01% 6421
2024
Q2 		$53.7K Sell
18,009
-24,109
-57% -$67K ﹤0.01% 6638
2024
Q1 		$145K Buy
42,118
+10,741
+34% +$24K ﹤0.01% 6048
2023
Q4 		$42K Buy
31,377
+8,802
+39% +$13.3K ﹤0.01% 6648
2023
Q3 		$49.2K Sell
22,575
-1,480
-6% -$3.34K ﹤0.01% 6296
2023
Q2 		$57.5K Buy
24,055
+16,475
+217% +$41.5K ﹤0.01% 6392
2023
Q1 		$14K Buy
7,580
+4,489
+145% +$10.2K ﹤0.01% 7369
2022
Q4 		$5.97K Sell
3,091
-1,186
-28% -$2.34K ﹤0.01% 9101
2022
Q3 		$7K Sell
4,277
-494
-10% -$1.62K ﹤0.01% 8908
2022
Q2 		$13K Buy
4,771
+3,147
+194% +$7.73K ﹤0.01% 7552
2022
Q1 		$4K Buy
+1,624
New +$1.68K ﹤0.01% 9324
2021
Q4 		– Sell
-5,173
Closed -$7K – 10720
2021
Q3 		$7K Buy
5,173
+3,036
+142% +$5.38K ﹤0.01% 8333
2021
Q2 		$5K Sell
2,137
-241
-10% -$543 ﹤0.01% 8573
2021
Q1 		$6K Buy
+2,378
New +$6.96K ﹤0.01% 8253
2020
Q2 		– Sell
-541
Closed -$2K – 8362
2020
Q1 		$2K Buy
+541
New +$2.46K ﹤0.01% 7645
2019
Q4 		– Sell
-1,577
Closed -$7K – 8418
2019
Q3 		$7K Sell
1,577
-344
-18% -$1.87K ﹤0.01% 7354
2019
Q2 		$14K Buy
+1,921
New +$16.5K ﹤0.01% 6857

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

UBS Group's TRVI Position: Q2 2026 in Review

UBS Group reduced its Trevi Therapeutics (TRVI) stake by 39% in Q2 2026, selling an estimated $2.56M and leaving 270,498 shares worth $5.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4152.

UBS Group first reported a position in TRVI in Q2 2019 and has held it in 24 quarters since. The position peaked at $5.32M in Q1 2026. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • UBS Group held 270,498 shares of Trevi Therapeutics worth $5.04M as of Q2 2026.
  • UBS Group sold 175,694 Trevi Therapeutics shares in Q2 2026, an estimated $2.56M.
  • Trevi Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4152 holding.
  • UBS Group first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • UBS Group's Trevi Therapeutics position peaked at $5.32M in Q1 2026.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.